Beyond Air, Inc. (XAIR)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN Summary
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Q2 2026 Earnings Call Transcript
Beyond Air, Inc. ( XAIR ) Q2 2026 Earnings Call November 10, 2025 4:30 PM EST Company Participants Steven Lisi - CEO & Chairman of the Board Douglas Larson - Chief Financial Officer Conference Call Participants Garth Russell - Lifesci Advisors, LLC Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd., Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Beyond Air financial results call for the fiscal quarter ended September 30, 2025.
Beyond Air, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KK Kent Keister Kaye Capital Management | 65.5 | $4,514.26 | $379.24 | -$4,135.02 | -91.6% |
 William Liberti Wealth Effects LLC | 1,417.75 | $65,500.05 | $8,286.75 | -$57,213.3 | -87.35% |
 David Vollmer PFS Partners, LLC | 100 | $4,620 | $598 | -$4,022 | -87.06% |
Beyond Air, Inc. (XAIR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Beyond Air, Inc. ever had a stock split?
Beyond Air, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Robert Goodman CEO | NASDAQ (CM) Exchange | 08862L202 CUSIP |
| US Country | 54 Employees | 10 Jan 2017 Last Dividend | 13 Jul 2026 Last Split | 22 Sep 2017 IPO Date |
Overview
Beyond Air, Inc. is a pioneering medical device and biopharmaceutical company with a focus on utilizing its innovative LungFit platform to address various pulmonary conditions. Situated in the United States and specifically operating out of Garden City, New York, the company marks its presence in the commercial-stage segment of the industry. Initially known as AIT Therapeutics, Inc., it underwent a rebranding in June 2019, adopting the name Beyond Air, Inc. This change reflects its broadening scope and commitment to advancing beyond traditional therapies to deliver innovative solutions for respiratory conditions. The core of its mission revolves around the development and commercialization of its proprietary nitric oxide generator and delivery systems designed to revolutionize the treatment paradigm for patients suffering from significant pulmonary diseases.
Products and Services
- LungFit PH - This system is tailored specifically for the treatment of persistent pulmonary hypertension of the newborn (PPHN), a condition that can cause significant morbidity and mortality in neonates. Its design allows for controlled and precise delivery of nitric oxide, which is critical in managing this condition effectively.
- LungFit PRO - Beyond Air is developing this iteration of the LungFit system to combat viral lung infections, including potentially life-threatening illnesses such as community-acquired viral pneumonia. Notably, it includes COVID-19 within its spectrum of targeted conditions, aiming to offer a viable treatment option for affected hospitalized patients. Moreover, LungFit PRO is also being tailored to address bronchiolitis, an infection that can severely affect infants and young children.
- LungFit GO - With a focus on addressing nontuberculous mycobacteria (NTM) infections, this version of the LungFit system aims to provide a solution to patients suffering from these often chronic, debilitating lung infections. NTM diseases represent a growing concern globally, and Beyond Air's commitment to offering an innovative treatment option underscores their dedication to addressing underserved medical needs.
